Vanguard Group’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,165,607
| Closed | -$55.8M | – | 4407 |
|
|
2025
Q3 | $55.8M | Sell |
1,165,607
-41,428
| -3% | -$1.15M | ﹤0.01% | 2107 |
|
|
2025
Q2 | $19.3M | Buy |
1,207,035
+16,225
| +1% | +$263K | ﹤0.01% | 2572 |
|
|
2025
Q1 | $18.1M | Buy |
1,190,810
+84,685
| +8% | +$1.36M | ﹤0.01% | 2553 |
|
|
2024
Q4 | $22.4M | Buy |
1,106,125
+43,652
| +4% | +$1.1M | ﹤0.01% | 2536 |
|
|
2024
Q3 | $27.3M | Buy |
1,062,473
+15,351
| +1% | +$256K | ﹤0.01% | 2446 |
|
|
2024
Q2 | $13.5M | Buy |
1,047,122
+132,603
| +14% | +$2.13M | ﹤0.01% | 2754 |
|
|
2024
Q1 | $20.9M | Buy |
914,519
+150,767
| +20% | +$5.32M | ﹤0.01% | 2575 |
|
|
2023
Q4 | $20M | Buy |
763,752
+653,689
| +594% | +$13.1M | ﹤0.01% | 2597 |
|
|
2023
Q3 | $3.09M | Buy |
110,063
+6,276
| +6% | +$184K | ﹤0.01% | 3442 |
|
|
2023
Q2 | $3.16M | Sell |
103,787
-8,708
| -8% | -$222K | ﹤0.01% | 3501 |
|
|
2023
Q1 | $2.11M | Buy |
112,495
+7,314
| +7% | +$121K | ﹤0.01% | 3652 |
|
|
2022
Q4 | $1.07M | Buy |
105,181
+3,481
| +3% | +$55.9K | ﹤0.01% | 3891 |
|
|
2022
Q3 | $2.67M | Sell |
101,700
-113
| -0.1% | -$4.12K | ﹤0.01% | 3621 |
|
|
2022
Q2 | $4.59M | Sell |
101,813
-1,261
| -1% | -$99.5K | ﹤0.01% | 3422 |
|
|
2022
Q1 | $10.1M | Sell |
103,074
-8
| -0% | -$749 | ﹤0.01% | 3144 |
|
|
2021
Q4 | $15.8M | Buy |
103,082
+63,664
| +162% | +$9.42M | ﹤0.01% | 2968 |
|
|
2021
Q3 | $5.34M | Buy |
39,418
+335
| +0.9% | +$45.9K | ﹤0.01% | 3615 |
|
|
2021
Q2 | $5.74M | Buy |
+39,083
| New | +$5.99M | ﹤0.01% | 3523 |
|
Vanguard Group's TRML Position: Q4 2025 in Review
Vanguard Group sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,165,607 shares — an estimated $55.8M sold.
Vanguard Group first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $55.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Vanguard Group reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Vanguard Group sold 1,165,607 Tourmaline Bio shares in Q4 2025, an estimated $55.8M.
- Vanguard Group first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Vanguard Group's Tourmaline Bio position peaked at $55.8M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.